APRETUDE FDA approval date

The FDA approved APRETUDE on 20 Dec 2021.

FDA approval date
20 Dec 2021

Drug identity has not yet been verified against registry records

Also recorded as CABOTEGRAVIR

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2021-12-20DayAPRETUDEFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA215499", "applicant_as_listed_by_fda": "VIIV HLTHCARE", "brand_names": ["APRETUDE"], "active_ingredients": ["CABOTEGRAVIR"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20211220", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026